Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786420 | 0.93 | PTPN1 (0.40) | PTGER1TP53MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL22791300 | 0.90 | ARF6 (0.39) | PTGER1MAPTSMN1; SMN2NPSR1CCR5 | |
| SCHEMBL21786468 | 0.90 | SLC6A4 (0.37) | PTGER1TP53MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL21786590 | 0.89 | NPSR1 (0.36) | PTGER1TP53MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL31635947 | 0.89 | SLC6A4 (0.37) | PTGER1TP53MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL21786625 | 0.89 | SMN1; SMN2 (0.36) | TP53MAPTSMN1; SMN2NPSR1PTPN1 | |
| SCHEMBL21786467 | 0.89 | SLC6A4 (0.37) | PTGER1TP53MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL21786535 | 0.88 | THRB (0.36) | PTGER1MAPTPTPN1THRBRAB9A | |
| SCHEMBL21786618 | 0.88 | SMN1; SMN2 (0.38) | TP53MAPTSMN1; SMN2NPSR1PTPN1 | |
| SCHEMBL21786627 | 0.88 | MAPT (0.41) | PTGER1MAPTNPSR1PTPN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | NORTHWESTERN UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| WO-2020257261-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020046382-A1 | SUBSTITUTED HETEROCYCLES AS C-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | PTGER1 4862/4885TP53 5/4885MDM2 134/4885 |
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | PTGER1 4862/4885TP53 5/4885MDM2 134/4885 |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | MYC, MYCBP, MYCBP2 | PTGER1 4862/4885TP53 5/4885MDM2 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.